Select the drug indication to add to your list


Bone disorders
Only 4 drugs may be compared at once

Generic Name and Formulations:

Teriparatide (recombinant) 250mcg/mL; soln for SC inj; contains m-cresol.

Select therapeutic use:

Indications for FORTEO:

Postmenopausal osteoporosis in women who are at high risk for fracture. To increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture. Treatment of men and women with osteoporosis associated with sustained glucocorticoid therapy at high risk for fracture (see literature).


20mcg SC once daily into thigh or abdominal wall; may treat for up to 2 years.


Not recommended.


Increased baseline risk for osteosarcoma (eg, Paget's disease of bone, unexplained increased alkaline phosphatase, open epiphyses, prior skeletal radiation therapy), bone metastases, history of skeletal malignancies, metabolic bone disease, hypercalcemia or risk thereof (eg, hyperparathyroidism): not recommended. Urolithiasis. Hypercalciuria. Hepatic, renal, or cardiac disease. Pregnancy (Cat.C). Nursing mothers: not recommended.


Caution with digoxin (teriparatide-induced hypercalcemia increases risk of toxicity).

Pharmacological Class:

Hormone (human parathyroid hormone, recombinant).

Adverse Reactions:

Arthralgia, pain, nausea; transient orthostatic hypotension, hypercalcemia, hyperuricemia, inj site reactions.

How Supplied:

Multidose Pen (2.4mL)—1

FORTEO 2.4ml of 20mcg/dose pens (Qty:1)

appx. price $3370.00